ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-PO745

Rapid Reduction in Urinary sCD163 Correlates with Clinical Benefit in the CLEAR Study of C5aR Inhibitor Avacopan in ANCA-Associated Vasculitis

Session Information

Category: Glomerular

  • 1004 Clinical/Diagnostic Renal Pathology and Lab Medicine

Authors

  • Deng, Jun, ChemoCentryx, Inc, Mountain View, California, United States
  • Potarca, Antonia, ChemoCentryx, Inc, Mountain View, California, United States
  • Schall, Thomas J., ChemoCentryx, Inc, Mountain View, California, United States
  • Bekker, Pirow, ChemoCentryx, Inc, Mountain View, California, United States
Background

Avacopan (CCX168), a potent C5aR inhibitor, induced rapid clinical benefit (measured by BVAS, proteinuria, and health-related quality of life measurements) in the Phase 2 CLEAR trial in ANCA-associated vasculitis, AAV (Jayne et al, JASN, 2017). Urinary soluble CD163 (sCD163) is a macrophage cell surface molecule known to correlate with renal histopathology, and it is a useful biomarker of kidney inflammation in AAV (O’Reilly et al, JASN, 2016). We evaluated urinary sCD163 in CLEAR patients at baseline and over the 12-week treatment period.

Methods

CLEAR comprised 3 patient groups: (1)Full dose prednisone (60 mg), standard care; (2)Avacopan 30 mg b.i.d. plus low dose prednisone (20 mg); (3)Avacopan 30 mg b.i.d. plus no prednisone. All patients received either IV cyclophosphamide or IV rituximab. sCD163 (ELISA) and creatinine were measured pre-dose, and days 8, 15, 29, 57, and 85.

Results

Avacopan treatment reduced sCD163/creatinine markedly by day 8, and further over the course of 12-weeks (see table). By contrast, standard care controls with full-dose prednisone therapy did not show improvement in urinary sCD163 until day 57. The urinary sCD163/creatinine levels were highly correlated with previously reported improvements in urinary albumin/creatinine ratio and MCP-1/creatinine ratio (p<0.0001).

Conclusion

Avacopan induced a rapid reduction of sCD163, which correlated with similarly rapid improvements of kidney inflammation markers and AAV signs and symptoms in the CLEAR trial. sCD163 may provide a valuable biomarker of clinical improvements derived from avacopan. Avacopan is currently in a Phase 3 clinical trial for AAV.

Urine sCD163/creatinine ng/mmole
 Placebo + FD PrednisoneAvacopan + LD PrednisoneAvacopan + No Prednisone
Time  95% CI  95% CI  95% CI
PointsN=GeomeanLowerUpperN=GeomeanLowerUpperN=GeomeanLowerUpper
Pre dose192581484482140828059618250137458
Day 81930018648521300*20743618180*110296
Day 151924914742321213***14232118165*89306
Day 291922014134221117***7817317117**63216
Day 5719116***7418220115***7018816125#71219
Day 8519120**771872085***501451897*50188

Paired t-test against baseline in each group: *p<0.05; **p<0.01; ***p<0.001; # p=0.076; FD = Full dose; LD = Low dose

Funding

  • Other NIH Support